
    
      The TaurusOne® transcatheter aortic valve system with retrievable delivery catheter system is
      evaluated the safety and effectiveness for the delivery of artificial aortic valve in a
      prospective, multicenter, single-arm clinical trial. According to the inclusion and exclusion
      criteria, sixty patients are planed been enrolled and implanted with TaurusOne® .Patients are
      seen at pre and post procedure, discharge, 30 days. The main follow-up included clinical
      symptoms and signs, cardiac ultrasound, CT, etc. The outcome included immediate device
      success, procedure success, And the major cardiovascular and cerebrovascular adverse events
      (MACCE, including mortality, stroke, myocardial infarction, reoperation, arrhythmia,
      conduction block).
    
  